Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -4.97%12 EV-to-EBITDA is -19.30 as of Sep. 18, 2026. GuruFocus rates AVLN with a GF Score™ of 12/100. Among 434 Biotechnology companies, Avalyn Pharma ranks worse than 230414.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avalyn Pharma's enterprise value is $1,066.49 Mil.
Avalyn Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-55.26 Mil. Therefore, Avalyn Pharma's EV-to-EBITDA for today is -19.30.
The historical rank and industry rank for Avalyn Pharma's EV-to-EBITDA or its related term are showing as below:
AVLN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.15 Med: 0 Max: 0
Current: -19.3
AVLN's EV-to-EBITDA is ranked worse than 100% of 434
companies
in the Biotechnology industry
Industry Median: 12.65
vs AVLN: -19.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avalyn Pharma's PE Ratio (TTM) for today is calculated as:
Avalyn Pharma's share price for today is $31.74.
Avalyn Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.259.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Avalyn Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma EV-to-EBITDA Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
EV-to-EBITDA
0.00
0.00
Avalyn Pharma Quarterly Data
Mar25
Jun25
Mar26
Jun26
EV-to-EBITDA
0.00
0.00
0.00
0.00
AVLN vs LBRX, LTGO, NVAX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Avalyn Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's EV-to-EBITDA falls into.
Avalyn Pharma's current Enterprise Value is $1,066.49 Mil.
Avalyn Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-55.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a EV-to-EBITDA of -19.30 as of Sep. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avalyn Pharma. According to the industry distribution chart, Avalyn Pharma ranks #999999 out of 434 companies in the Biotechnology industry.
Is Avalyn Pharma's EV-to-EBITDA too high?
Avalyn Pharma's current EV-to-EBITDA is -19.30. Based on the distribution chart, Avalyn Pharma ranks #999999 out of 434 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalyn Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's EV-to-EBITDA compare to LBRX and LTGO?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #999999 out of 434 companies for EV-to-EBITDA. This places Avalyn Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 12.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.65, based on 434 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avalyn Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 12.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current EV-to-EBITDA is -19.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current EV-to-EBITDA of -19.30. The current EV-to-EBITDA is -19.30. Avalyn Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current EV-to-EBITDA is -19.30 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score
Get the complete analysis for AVLN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
